Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rabeprazole + amoxicillin + tetracycline + furazolidone + colloidal bismuth pectin
- Development stage
- Unknown
- Lead developer
- Shandong University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This drug is a 14-day modified sequential therapy regimen investigated by Shandong University for the rescue treatment of refractory Helicobacter pylori infection. The treatment protocol is divided into two 7-day stages: the first stage involves the administration of double-dose rabeprazole, amoxicillin, tetracycline, and furazolidone; the second stage replaces furazolidone with colloidal bismuth pectin while maintaining the other three components. Rabeprazole serves as a proton pump inhibitor to maintain an alkaline gastric environment, while amoxicillin and tetracycline inhibit bacterial cell wall and protein synthesis, respectively. Furazolidone provides potent antibacterial activity through DNA damage, and colloidal bismuth pectin offers mucosal protection and direct bactericidal effects against H. pylori.
- Other names
- Modified sequential therapy (Shandong University)
02
Targets
Bacterial RibosomePBP (Penicillin-binding protein family)NeuraminidaseATP4A (Potassium–transporting ATPase alpha chain 1)Bismuth-sensitive bacterial enzymes and membrane-associated targetsMAOA (Monoamine oxidase A)
Beyond the preview
Go deeper on rabeprazole + amoxicillin + tetracycline + furazolidone + colloidal bismuth pectin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rabeprazole + amoxicillin + tetracycline + furazolidone + colloidal bismuth pectin.